Embed Size (px)
Citation preview
Percentage of Penicillin Non-SusceptiblePercentage of Penicillin Non-Susceptible S. pneumoniaeS. pneumoniae in Canada: 1988-2009 in Canada: 1988-2009
Canadian Bacterial Surveillance Network, Jun 2010
0
5
10
15
20
25
1988
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
% intermediate resistance
% high-level resistance
*Non-meningitis, Oral pen breakpoints used
Percentage of Penicillin* Non-SusceptiblePercentage of Penicillin* Non-Susceptible S. pneumoniaeS. pneumoniae in Canada: 1993-2009 in Canada: 1993-2009
Canadian Bacterial Surveillance Network, Jun 2010
0
1
2
3
4
5
6
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
% intermediate resistance
% high-level resistance
*Non-meningitis, IV breakpoints used
Percentage of Non-susceptible Sterile Site vs Non-sterile Percentage of Non-susceptible Sterile Site vs Non-sterile Site Isolates ofSite Isolates of S. pneumoniae, S. pneumoniae, 20092009
Canadian Bacterial Surveillance Network, Jun 2010
0
5
10
15
20
25
30
Per
cent
age
(%)
Non
-sus
cept
ible
Pen Erythro Clinda Ceftriaxone Cipro Tetracycline Tmp/Smx
Sterile
Non-sterile
*Non-meningitis breakpoints used, Non-meningitis (IV) for pen
Percentage of Amoxicillin Non-SusceptiblePercentage of Amoxicillin Non-Susceptible S. pneumoniaeS. pneumoniae in Canada: 1988-2009 in Canada: 1988-2009
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
1988
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
% low-level resistance
% resistance
Canadian Bacterial Surveillance Network, Jun 2010
Percentage of Non-susceptible Isolates ofPercentage of Non-susceptible Isolates of S. pneumoniae S. pneumoniae in Ages <=15 and >64, 2009in Ages <=15 and >64, 2009
Canadian Bacterial Surveillance Network, Jun 2010
0
5
10
15
20
25
30
Pe
rce
nta
ge
(%
) n
on
-su
sce
ptib
le
Pen Erythro Clinda Ceftriaxone Cipro Tetracycline Tmp/Smx
Age <=15 yrs
Age >64 yrs
*Non-meningitis breakpoints used, Non-meningitis (IV) for pen
Percentage of Non-susceptible Isolates ofPercentage of Non-susceptible Isolates ofS. pneumoniae S. pneumoniae in Geographic Regions of Canada, 2009in Geographic Regions of Canada, 2009
Canadian Bacterial Surveillance Network, Jun 2010
0
5
10
15
20
25
30
BC PRAIRIES ONT Atlantic
Levo Ceftri (Non-mening) Pen Clind Eryth
*Non-meningitis breakpoints used
Macrolide-Resistant Pneumococci: Macrolide-Resistant Pneumococci: Canadian Bacterial Surveillance Network, 1993-2009Canadian Bacterial Surveillance Network, 1993-2009
Canadian Bacterial Surveillance Network, Jun 2010
0
5
10
15
20
25
Per
cent
age
of I
sola
tes
Res
ista
nt t
oE
ryth
rom
ycin
1988
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Fluoroquinolone-Resistant Pneumococci:Fluoroquinolone-Resistant Pneumococci: Canadian Bacterial Surveillance Network, 1997-2009Canadian Bacterial Surveillance Network, 1997-2009
Canadian Bacterial Surveillance Network, Jun 2010
% R
esis
tant
0
0.5
1
1.5
2
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Moxifloxacin
Levofloxacin
Fluoroquinolone-Resistant Pneumococci in Respiratory Fluoroquinolone-Resistant Pneumococci in Respiratory Isolates from Adults >64 years: 1988-2009Isolates from Adults >64 years: 1988-2009
0
1
2
3
4
5
6
7
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
0
20
40
60
80
100
120
Levo R Moxi R All quinolone Use
Cipro Use Levo Use Moxi
0
10
20
30
40
50
60
70
80
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Year
% o
f is
olat
es
PCV7 PCV10 additional serotypes (1,5,7F) PCV13 additional serotypes (3,6A,19A) NPCV
Serotype distribution by year: 1994-2009Serotype distribution by year: 1994-2009
0
5
10
15
20
25
30
35
40
45
18C 14 9V 23F 9N 6B 4 19A 6A 11A 7F 3 19F Other
Year
% o
f is
olat
es
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 20052006 2007 2008 2009
Serotype distribution by year: 1994-2009Serotype distribution by year: 1994-2009
![KPC-Producing Klebsiella pneumoniae Strains: A Threat to ... · were susceptible to amikacin, tigecycline, gentamicin or colistin [49,50,17,46]. This leaves colistin as the sole therapeutic](https://img.pdfslide.net/doc/110x75/6096566836f3ec021f08deb2/kpc-producing-klebsiella-pneumoniae-strains-a-threat-to-were-susceptible-to.jpg)
